Ji-Jing Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ji-Jing Yan has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Jaeseok Yang
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
8 shared publications - Curie Ahn
Division of Nephrology, National Medical Center, Seoul, South Korea
4 shared publications - Jae-Ghi Lee
Transplantation Research Institute, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea
3 shared publications - Joon Young Jang
Division of Nephrology, Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, Republic of Korea
3 shared publications - Miyeun Han
Department of Internal Medicine, National Medical Center, Seoul, Republic of Korea
3 shared publications - Beom Seok Kim
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
2 shared publications
Latest Publications
- Open Access
- 1 March 2026
- Published by Wiley in Xenotransplantation
- Vol. 33 (2) , e70126
Donor‐Derived Cell‐Free DNA (dd‐cfDNA) as an Early Noninvasive Biomarker of Graft Injury in Pig‐to‐Monkey Islet Xenotransplantation
Background: In pig‐to‐nonhuman primate islet transplantation, reliable, sensitive biomarkers are needed to detect graft damage at an early stage before irreversible islet loss occurs. In our study, we investigated donor‐derived cell‐free DNA (dd‐cfDNA) as an early, noninvasive biomarker of graft injury by analyzing its correlation with porcine C‐peptide levels, complement activation markers, and donor‐specific antibodies (DSAs). Methods: Streptozotocin‐induced diabetic cynomolgus monkeys received 50 000–100 000 IEQ/kg of intraportal islets from quadruple‐knockout (QKO; GGTA1 , CMAH , B4GALNT2 , and A3GALT2 ) pigs. Cohort 1 received antithymocyte globulin (ATG), tacrolimus, mycophenolate mofetil (MMF), and anti‐inflammatory agents (i.e., anakinra, adalimumab, and tocilizumab), whereas Cohort 2 received the same regimen plus rituximab and crovalimab. Graft function and immune responses were assessed by measuring porcine C‐peptide levels, complement activation markers, histology, and dd‐cfDNA kinetics. Results: Cohort 1 showed transient porcine C‐peptide secretion with marked dd‐cfDNA elevation at 7 d postoperatively that coincided with complement activation (i.e., C5a and membrane attack complex (MAC)) and dense CD3 + T‐cell and CD68 + macrophage infiltration, which resulted in early graft loss. Cohort 2 maintained stable C‐peptide levels, lower dd‐cfDNA levels, and reduced complement activation with improved graft preservation. Moreover, dd‐cfDNA correlated negatively with C‐peptide and positively with C5a but not with MAC. In both cohorts, DSA levels remained unchanged. Conclusions: Our study revealed that dd‐cfDNA levels correlate with graft damage and C5a in QKO porcine islet xenografts, which corroborates dd‐cfDNA utility as an early biomarker for predicting instant blood‐mediated inflammatory reaction (IBMIR). These findings indicate that dd‐cfDNA may be able to detect early islet xenograft damage.
- 1 March 2026
- Published by Wiley in Xenotransplantation
- Vol. 33 (2) , e70126
Open AccessDonor‐Derived Cell‐Free DNA (dd‐cfDNA) as an Early Noninvasive Biomarker of Graft Injury in Pig‐to‐Monkey Islet Xenotransplantation
Background: In pig‐to‐nonhuman primate islet transplantation, reliable, sensitive biomarkers are needed to detect graft damage at an early stage before irreversible islet loss occurs. In our study, we investigated donor‐derived cell‐free DNA (dd‐cfDNA) as an early, noninvasive biomarker of graft injury by analyzing its correlation with porcine C‐peptide levels, complement activation markers, and donor‐specific antibodies (DSAs). Methods: Streptozotocin‐induced diabetic cynomolgus monkeys received 50 000–100 000 IEQ/kg of intraportal islets from quadruple‐knockout (QKO; GGTA1 , CMAH , B4GALNT2 , and A3GALT2 ) pigs. Cohort 1 received antithymocyte globulin (ATG), tacrolimus, mycophenolate mofetil (MMF), and anti‐inflammatory agents (i.e., anakinra, adalimumab, and tocilizumab), whereas Cohort 2 received the same regimen plus rituximab and crovalimab. Graft function and immune responses were assessed by measuring porcine C‐peptide levels, complement activation markers, histology, and dd‐cfDNA kinetics. Results: Cohort 1 showed transient porcine C‐peptide secretion with marked dd‐cfDNA elevation at 7 d postoperatively that coincided with complement activation (i.e., C5a and membrane attack complex (MAC)) and dense CD3 + T‐cell and CD68 + macrophage infiltration, which resulted in early graft loss. Cohort 2 maintained stable C‐peptide levels, lower dd‐cfDNA levels, and reduced complement activation with improved graft preservation. Moreover, dd‐cfDNA correlated negatively with C‐peptide and positively with C5a but not with MAC. In both cohorts, DSA levels remained unchanged. Conclusions: Our study revealed that dd‐cfDNA levels correlate with graft damage and C5a in QKO porcine islet xenografts, which corroborates dd‐cfDNA utility as an early biomarker for predicting instant blood‐mediated inflammatory reaction (IBMIR). These findings indicate that dd‐cfDNA may be able to detect early islet xenograft damage.
- Open Access
- 28 July 2021
- Published by Elsevier in Genes & Diseases
- Vol. 9 (1) , 1-4
Anti-C4d chimeric antigen receptor regulatory T cells suppressed allograft rejection in ABO-incompatible heart transplantation
- 28 July 2021
- Published by Elsevier in Genes & Diseases
- Vol. 9 (1) , 1-4
Open AccessAnti-C4d chimeric antigen receptor regulatory T cells suppressed allograft rejection in ABO-incompatible heart transplantation
- Open Access
- 28 May 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (22) , eabg2237
Tissue-engineered vascular microphysiological platform to study immune modulation of xenograft rejection
Tissue-engineered vascular microphysiological platform is applicable for evaluating immune modulation of xenograft rejection.
- 28 May 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (22) , eabg2237
Open AccessTissue-engineered vascular microphysiological platform to study immune modulation of xenograft rejection
Tissue-engineered vascular microphysiological platform is applicable for evaluating immune modulation of xenograft rejection.
- Open Access
- 12 February 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (2) , e0246967
Suppressive effects of vitamin C-treated induced-regulatory T cells on heart allograft rejection under vitamin C-deficient or –sufficient conditions
Foxp3 stability of vitamin C-treated induced-regulatory T cells (V-iTregs) is superior to that of conventional iTregs (C-iTregs). However, the role of V-iTregs in allograft rejection under vitamin C-deficient conditions, such as those seen in humans, remains unclear. We aimed to elucidate the role of vitamin C treatment on generation and maintenance of iTregs from gulo knockout (Gulo-KO) mice as well as wild type (WT) mice, and in vitro and in vivo suppressive effects of V-iTregs on heart allograft rejection in either Gulo-KO or WT recipient mice. Conversion efficiency of iTregs was similar between C- and V-iTregs in both WT and Gulo-KO mice. V-iTregs from WT or Gulo-KO mice showed better in vitro Foxp3 stability than C-iTregs, although there was no difference between WT V-iTregs and Gulo-KO V-iTregs. Furthermore, V-iTregs from WT or Gulo-KO mice suppressed in vitro T cell proliferation better than C-iTregs. Heterotrophic heart transplantation from BALB/c mice to WT or vitamin C-deficient Gulo-KO C57BL/6J mice was performed following adoptive transfer of C- or V-iTregs. V-iTregs as well as C-iTregs prolonged heart allograft survival in WT and Gulo-KO mice. However, there was no difference between the C- and V-iTreg groups. Supplementation of low- or high-dose vitamin C did not induce significant changes in heart allograft survival in Gulo-KO recipients that had received V-iTregs. In conclusion, V-iTregs do not exert better suppressive effects on heart allograft survival than C-iTregs in either WT or vitamin C-deficient recipients.
- 12 February 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (2) , e0246967
Open AccessSuppressive effects of vitamin C-treated induced-regulatory T cells on heart allograft rejection under vitamin C-deficient or –sufficient conditions
Foxp3 stability of vitamin C-treated induced-regulatory T cells (V-iTregs) is superior to that of conventional iTregs (C-iTregs). However, the role of V-iTregs in allograft rejection under vitamin C-deficient conditions, such as those seen in humans, remains unclear. We aimed to elucidate the role of vitamin C treatment on generation and maintenance of iTregs from gulo knockout (Gulo-KO) mice as well as wild type (WT) mice, and in vitro and in vivo suppressive effects of V-iTregs on heart allograft rejection in either Gulo-KO or WT recipient mice. Conversion efficiency of iTregs was similar between C- and V-iTregs in both WT and Gulo-KO mice. V-iTregs from WT or Gulo-KO mice showed better in vitro Foxp3 stability than C-iTregs, although there was no difference between WT V-iTregs and Gulo-KO V-iTregs. Furthermore, V-iTregs from WT or Gulo-KO mice suppressed in vitro T cell proliferation better than C-iTregs. Heterotrophic heart transplantation from BALB/c mice to WT or vitamin C-deficient Gulo-KO C57BL/6J mice was performed following adoptive transfer of C- or V-iTregs. V-iTregs as well as C-iTregs prolonged heart allograft survival in WT and Gulo-KO mice. However, there was no difference between the C- and V-iTreg groups. Supplementation of low- or high-dose vitamin C did not induce significant changes in heart allograft survival in Gulo-KO recipients that had received V-iTregs. In conclusion, V-iTregs do not exert better suppressive effects on heart allograft survival than C-iTregs in either WT or vitamin C-deficient recipients.
- Open Access
- 1 January 2020
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 40 (1) , 48-56
Human B1 Cells are the Main Blood Group A-Specific B Cells That Have a Moderate Correlation With Anti-A Antibody Titer
Xu Y, et al. Ann Lab Med. 2020 Jan;40(1):48-56. https://doi.org/10.3343/alm.2020.40.1.48
- 1 January 2020
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 40 (1) , 48-56
Open AccessHuman B1 Cells are the Main Blood Group A-Specific B Cells That Have a Moderate Correlation With Anti-A Antibody Titer
Xu Y, et al. Ann Lab Med. 2020 Jan;40(1):48-56. https://doi.org/10.3343/alm.2020.40.1.48
- 4 May 2018
- Published by Elsevier in Transplantation Proceedings
- Vol. 50 (4) , 1056-1062
VDJ Gene Usage of B Cell Receptors in Peripheral Blood of ABO-incompatible Kidney Transplantation Patients
- 4 May 2018
- Published by Elsevier in Transplantation Proceedings
- Vol. 50 (4) , 1056-1062
VDJ Gene Usage of B Cell Receptors in Peripheral Blood of ABO-incompatible Kidney Transplantation Patients
- Open Access
- 28 November 2017
- Published by Springer Nature in BMC Nephrology
- Vol. 18 (1) , 340
VDJ gene usage among B-cell receptors in ABO-incompatible kidney transplantation determined by RNA-seq Transcriptomic analysis
Studies on B-cell subtypes and V(D)J gene usage of B-cell receptors in kidney transplants are scarce. This study aimed to investigate V(D)J gene segment usage in ABO-incompatible (ABOi) kidney transplant (KT) patients compared to that in ABO-compatible (ABOc) KT patients. We selected 16 ABOi KT patients with accommodation (ABOiA), 6 ABOc stable KT patients (ABOcS), and 6 ABOi KT patients with biopsy-proven acute antibody-mediated rejection (ABOiR) at day 10, whose graft tissue samples had been stored in the biorepository between 2010 and 2014. Complete transcriptomes of graft tissues were sequenced and analyzed through RNA sequencing (RNA-seq). The international ImMunoGeneTics information system (IMGT®) was used for in-depth comparison of V(D)J gene segment usage. The mean age of the 28 KT recipients was 43.3 ± 12.8 years, and 53.6% were male. By family, IGHV3, IGHJ4, IGLV2, and IGLJ3 gene segments were most frequently used in all groups, and their usage was not statistically different among the three patient groups. While IGKV3 was most frequently used in both the ABOiA and ABOiR groups, IGKV1 was most commonly used in the ABOcS group. In addition, while IGKJ1 was most commonly used in the ABOiA and ABOcS groups, IGKJ4 was most frequently used in the ABOiR group. According to individual gene segments, IGHV4–34 and IGHV4–30-2 were more commonly used in the ABOiR group than in the ABOiA group, and IGHV6–1 was more commonly used in the ABOcS group than in the ABOiR group. IGLV7–43 was more commonly used in the ABOcS group than in the ABOi group. However, technical variability, small sample size, and potential confounding effects of Rituximab or HLA mismatching are limitations of our study. Our findings suggest that RNA-seq transcriptomic analyses can provide information on the V(D)J gene usage of B-cell receptors and the mechanisms of accommodation and immune reaction in ABOi KT.
- 28 November 2017
- Published by Springer Nature in BMC Nephrology
- Vol. 18 (1) , 340
Open AccessVDJ gene usage among B-cell receptors in ABO-incompatible kidney transplantation determined by RNA-seq Transcriptomic analysis
Studies on B-cell subtypes and V(D)J gene usage of B-cell receptors in kidney transplants are scarce. This study aimed to investigate V(D)J gene segment usage in ABO-incompatible (ABOi) kidney transplant (KT) patients compared to that in ABO-compatible (ABOc) KT patients. We selected 16 ABOi KT patients with accommodation (ABOiA), 6 ABOc stable KT patients (ABOcS), and 6 ABOi KT patients with biopsy-proven acute antibody-mediated rejection (ABOiR) at day 10, whose graft tissue samples had been stored in the biorepository between 2010 and 2014. Complete transcriptomes of graft tissues were sequenced and analyzed through RNA sequencing (RNA-seq). The international ImMunoGeneTics information system (IMGT®) was used for in-depth comparison of V(D)J gene segment usage. The mean age of the 28 KT recipients was 43.3 ± 12.8 years, and 53.6% were male. By family, IGHV3, IGHJ4, IGLV2, and IGLJ3 gene segments were most frequently used in all groups, and their usage was not statistically different among the three patient groups. While IGKV3 was most frequently used in both the ABOiA and ABOiR groups, IGKV1 was most commonly used in the ABOcS group. In addition, while IGKJ1 was most commonly used in the ABOiA and ABOcS groups, IGKJ4 was most frequently used in the ABOiR group. According to individual gene segments, IGHV4–34 and IGHV4–30-2 were more commonly used in the ABOiR group than in the ABOiA group, and IGHV6–1 was more commonly used in the ABOcS group than in the ABOiR group. IGLV7–43 was more commonly used in the ABOcS group than in the ABOi group. However, technical variability, small sample size, and potential confounding effects of Rituximab or HLA mismatching are limitations of our study. Our findings suggest that RNA-seq transcriptomic analyses can provide information on the V(D)J gene usage of B-cell receptors and the mechanisms of accommodation and immune reaction in ABOi KT.
- Open Access
- 15 November 2016
- Published by Springer Nature in BMC Nephrology
- Vol. 17 (1) , 1-12
Granulocyte colony-stimulating factor treatment ameliorates lupus nephritis through the expansion of regulatory T cells
Granulocyte colony-stimulating factor (G-CSF) can induce regulatory T cells (Tregs) as well as myeloid-derived suppressor cells (MDSCs). Despite the immune modulatory effects of G-CSF, results of G-CSF treatment in systemic lupus erythematosus are still controversial. We therefore investigated whether G-CSF can ameliorate lupus nephritis and studied the underlying mechanisms. NZB/W F1 female mice were treated with G-CSF or phosphate-buffered saline for 5 consecutive days every week from 24 weeks of age, and were analyzed at 36 weeks of age. G-CSF treatment decreased proteinuria and serum anti-dsDNA, increased serum complement component 3 (C3), and attenuated renal tissue injury including deposition of IgG and C3. G-CSF treatment also decreased serum levels of BUN and creatinine, and ultimately decreased mortality of NZB/W F1 mice. G-CSF treatment induced expansion of CD4+CD25+Foxp3+ Tregs, with decreased renal infiltration of T cells, B cells, inflammatory granulocytes and monocytes in both kidneys and spleen. G-CSF treatment also decreased expression levels of MCP-1, IL-6, IL-2, and IL-10 in renal tissues as well as serum levels of MCP-1, IL-6, TNF-α, IL-10, and IL-17. When Tregs were depleted by PC61 treatment, G-CSF-mediated protective effects on lupus nephritis were abrogated. G-CSF treatment ameliorated lupus nephritis through the preferential expansion of CD4+CD25+Foxp3+ Tregs. Therefore, G-CSF has a therapeutic potential for lupus nephritis.
- 15 November 2016
- Published by Springer Nature in BMC Nephrology
- Vol. 17 (1) , 1-12
Open AccessGranulocyte colony-stimulating factor treatment ameliorates lupus nephritis through the expansion of regulatory T cells
Granulocyte colony-stimulating factor (G-CSF) can induce regulatory T cells (Tregs) as well as myeloid-derived suppressor cells (MDSCs). Despite the immune modulatory effects of G-CSF, results of G-CSF treatment in systemic lupus erythematosus are still controversial. We therefore investigated whether G-CSF can ameliorate lupus nephritis and studied the underlying mechanisms. NZB/W F1 female mice were treated with G-CSF or phosphate-buffered saline for 5 consecutive days every week from 24 weeks of age, and were analyzed at 36 weeks of age. G-CSF treatment decreased proteinuria and serum anti-dsDNA, increased serum complement component 3 (C3), and attenuated renal tissue injury including deposition of IgG and C3. G-CSF treatment also decreased serum levels of BUN and creatinine, and ultimately decreased mortality of NZB/W F1 mice. G-CSF treatment induced expansion of CD4+CD25+Foxp3+ Tregs, with decreased renal infiltration of T cells, B cells, inflammatory granulocytes and monocytes in both kidneys and spleen. G-CSF treatment also decreased expression levels of MCP-1, IL-6, IL-2, and IL-10 in renal tissues as well as serum levels of MCP-1, IL-6, TNF-α, IL-10, and IL-17. When Tregs were depleted by PC61 treatment, G-CSF-mediated protective effects on lupus nephritis were abrogated. G-CSF treatment ameliorated lupus nephritis through the preferential expansion of CD4+CD25+Foxp3+ Tregs. Therefore, G-CSF has a therapeutic potential for lupus nephritis.
- Open Access
- 16 January 2016
- Published by Springer Nature in BMC Urology
- Vol. 16 (1) , 1-11
Effects of stimulating interleukin -2/anti- interleukin -2 antibody complexes on renal cell carcinoma
Current therapies for advanced renal cell carcinoma (RCC) have low cure rates or significant side effects. It has been reported that complexes composed of interleukin (IL)-2 and stimulating anti-IL-2 antibody (IL-2C) suppress malignant melanoma growth. We investigated whether it could have similar effects on RCC. A syngeneic RCC model was established by subcutaneously injecting RENCA cells into BALB/c mice, which were administered IL-2C or phosphate-buffered saline every other day for 4 weeks. RCC size was measured serially, and its weight was assessed 4 weeks after RENCA injection. Immune cell infiltration into RCC lesions and spleen was assessed by flow cytometry and immunohistochemistry. IL-2C treatment increased the numbers of CD8+ memory T and natural killer (NK) cells in healthy BALB/c mice (P < 0.01). In the spleen of RCC mice, IL-2C treatment also increased the number of CD8+ memory T, NK cells, and macrophages as compared to PBS-treated controls (P < 0.01). The number of interferon-γ- and IL-10-producing splenocytes increased and decreased, respectively after 4 weeks in the IL-2C-treated mice (P < 0.01). Tumor-infiltrating immune cells including CD4+ T, CD8+ T, NK cells as well as macrophages were increased in IL-2C-treated mice than controls (P < 0.05). Pulmonary edema, the most serious side effect of IL-2 therapy, was not exacerbated by IL-2C treatment. However, IL-2C had insignificant inhibitory effect on RCC growth (P = 0.1756). IL-2C enhanced immune response without significant side effects; however, this activity was not sufficient to inhibit RCC growth in a syngeneic, murine model.
- 16 January 2016
- Published by Springer Nature in BMC Urology
- Vol. 16 (1) , 1-11
Open AccessEffects of stimulating interleukin -2/anti- interleukin -2 antibody complexes on renal cell carcinoma
Current therapies for advanced renal cell carcinoma (RCC) have low cure rates or significant side effects. It has been reported that complexes composed of interleukin (IL)-2 and stimulating anti-IL-2 antibody (IL-2C) suppress malignant melanoma growth. We investigated whether it could have similar effects on RCC. A syngeneic RCC model was established by subcutaneously injecting RENCA cells into BALB/c mice, which were administered IL-2C or phosphate-buffered saline every other day for 4 weeks. RCC size was measured serially, and its weight was assessed 4 weeks after RENCA injection. Immune cell infiltration into RCC lesions and spleen was assessed by flow cytometry and immunohistochemistry. IL-2C treatment increased the numbers of CD8+ memory T and natural killer (NK) cells in healthy BALB/c mice (P < 0.01). In the spleen of RCC mice, IL-2C treatment also increased the number of CD8+ memory T, NK cells, and macrophages as compared to PBS-treated controls (P < 0.01). The number of interferon-γ- and IL-10-producing splenocytes increased and decreased, respectively after 4 weeks in the IL-2C-treated mice (P < 0.01). Tumor-infiltrating immune cells including CD4+ T, CD8+ T, NK cells as well as macrophages were increased in IL-2C-treated mice than controls (P < 0.05). Pulmonary edema, the most serious side effect of IL-2 therapy, was not exacerbated by IL-2C treatment. However, IL-2C had insignificant inhibitory effect on RCC growth (P = 0.1756). IL-2C enhanced immune response without significant side effects; however, this activity was not sufficient to inhibit RCC growth in a syngeneic, murine model.